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Abstract
Vertical transmission of human immunodeficiency virus (HIV) represents an important world-wide health problem although the inci-
dence in developed countries has been drastically reduced by the extensive use of highly active antiretroviral therapy. Vertically HIV-
infected subjects have been exposed to the virus during the maturation of their immune systems and have suffered a persistent
chronic activation throughout their lifetime; the consequences of this situation for their immune system are not fully understood.
The objective of this study was to analyse immunosenescence-related parameters in different CD4 T-cell subsets. Fifty-seven vertically
HIV-infected subjects and 32 age-matched healthy subjects were studied. Activation (HLA) DR+), senescence (CD28) CD57+) and
proliferation (Ki67+) were analysed on different CD4 T-cell subsets: naive (CD45RA+ CD27+), memory (CD45RO+ CD27+), effector
memory (CD45RO+ CD27)) and effector memory RA (CD45RA+ CD27)). Compared with healthy subjects, vertically HIV-infected
subjects showed increased naive and memory CD4 T-cell frequencies (p 0.035 and p 0.010, respectively) but similar frequencies of
both effector subsets. Whereas naive CD4 T cells were not further altered, memory CD4 T cells presented increased levels of
senescence and proliferation markers (p <0.001), effector memory CD4 T cells presented increased levels of activation, senescence
and proliferation markers (p <0.001) and effector memory RA CD4 T cells presented increased levels of activation and senescence
(p <0.001) compared with healthy subjects. Despite long periods of infection, vertically HIV-infected subjects show specific patterns
of immunosenescence, revealing a preserved CD4 T-cell homeostasis for subset differentiation and distribution. Nevertheless, except-
ing the naive subpopulation, all subsets experienced some immunosenescence, pointing to uncertain consequences of the future aging
process in these subjects.
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Introduction
Nowadays mother-to-child transmission of human immuno-
deficiency virus (HIV) remains a major worldwide health
problem, with a yearly estimate of 370 000 new paediatric
infections [1]. In resource-rich countries the use of highly
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active antiretroviral therapy (HAART) has decreased the ver-
tical transmission of HIV-1 to rates as low as 0.99% [2] and
reduced infant mortality by around 75%. However, contin-
uing treatment for life is problematic, given the limitations of
the available drugs, the long-term toxicity of antiretroviral
therapy and adherence issues [3].
Increasing evidence suggests that HIV infection drives an
immune exhaustion similar to that driven by age in unin-
fected elderly subjects [4–6]. Activation and inflammation
due to HIV infection generate an accelerated replicative
senescence of T cells [7] and changes in immune homeo-
static mechanisms. Both alterations, together with a
reduced thymic function, result in an imbalance in T-cell
phenotypes [8,9]. In addition, as a unique feature, vertically
HIV-infected subjects have been infected in the course of
their immune system’s maturation and have suffered a per-
sistent chronic activation throughout their lifetime. Several
reports have described immune reconstitution in HIV-
infected subjects after HAART, giving a relevant role to the
thymus [10–15]. Some reports have characterized different
T-cell subsets and compared their distribution with that in
healthy subjects [16,17]. Although the premature aging of
the immune system caused by chronic HIV infection is well
documented [4], no data exist in relation to this phenome-
non in vertical infection and, as far as we know, no previ-
ous study has analysed CD4 T-cell phenotypes in relation
to immunosenescence features in vertically HIV-infected
subjects.
In this study we have performed an exhaustive CD4 T-cell
phenotypic analysis to evaluate immunosenescence-related
features in different CD4 T-cell subsets in vertically HIV-
infected subjects.
Materials and Methods
Study subjects
We carried out a cross-sectional study on a cohort
of patients vertically infected with HIV-1 from the
Infectious Diseases Service at Virgen del Rocı´o University
Hospital (Sevilla, Spain), from the Immuno Paediatric Unit at
Hospital General Universitario Gregorio Maran˜o´n (Madrid,
Spain) and from La Paz University Hospital (Madrid, Spain).
Fifty-seven consecutive asymptomatic vertically HIV-1-
infected subjects, attending outpatient visits between Decem-
ber 2008 and July 2010, were included. In addition, we
included 32 age-matched HIV-negative healthy subjects as a
control group. Informed consent was obtained from all sub-
jects or from their legal guardians as appropriate. The study
was approved by the ethics committees of all participating
hospitals. Fresh samples from patients were partially pro-
cessed by the Laboratory from IBIS (Seville) and the Paediat-
ric HIV BioBank (Madrid) [18].
Laboratory measurements
Absolute CD4 T-cell numbers were determined in fresh
blood with an Epics XL-MCL flow cytometer (Beckman-
Coulter, Brea, CA, USA). Plasma HIV-1 RNA levels were
measured by quantitative PCR (COBAS Ampliprep/COBAS
Taqman HIV-1 test, Roche Molecular Systems, Pleasanton,
CA, USA), according to the manufacturer’s instructions.
Detection limit was 40 HIV-RNA copies/mL.
Cellular immunophenotype
The CD4 peripheral T-cell subset was positively selected
from fresh peripheral blood mononuclear cells using mag-
netic microbeads from MACS Cell Separation Reagents
(Miltenyi Biotec, Bergisch Gladbach, Germany) according to
the manufacturer’s instructions (purity over 90% in all cases).
CD4+ isolated T cells were then stained using different
monoclonal antibodies: CD45RO-phycoerythrin Cychrome 7
(PECy7), Ki67-PE (Becton Dickinson, San Jose, CA, USA);
CD45RA-PE Texas Red-X, CD27-PECy5, CD57-fluorescein
isothiocyanate, CD28-PE and HLADR-PECy5 (Beckman
Coulter, Kendall, FL, USA). CD4+ The T-cell subsets were
defined as follows: naive (CD45RA+ CD27+); memory
(CD45RO+ CD27+); effector memory (CD45RO+ CD27))
and effector memory RA+ (TemRA) (CD45RA+ CD27)).
The accuracy of these phenotypes has been recently
reported [19]. Cellular activation in CD4 subsets was charac-
terized by HLA-DR expression [20]. Senescent CD4+ T cells
were characterized as CD28) CD57+. Proliferation levels
were determined by intracellular immunostaining with Ki67.
Cells were permeabilized using the fixation/permeabilization
staining set (eBioscience, San Diego, CA, USA) according to
the manufacturer’s instructions. Data on a minimum of
100 000 events were acquired. Acquisition was performed
on a Cytomics FC500 flow cytometer and analysis used CXP
software (Beckman Coulter).
Statistical analysis
All continuous variables were expressed as a median for
each variable (interquartile range), and categorical variables
as the number of cases and percentages. Differences among
categorical variables were analysed using the chi-squared
test. The Mann–Witney non-parametric U test was used to
analyse differences between continuous variables. Correla-
tions between quantitative parameters were explored using
the Spearman’s rho correlation coefficient. Statistical analysis
was performed using Statistical Package for the Social Sci-
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ences software (SPSS 17, Chicago, IL, USA). A p value <0.05
was considered statistically significant.
Results
Characteristics of the subjects
Fifty-seven vertically HIV-infected subjects (14 years old; inter-
quartile range 11–17 years) and 32 healthy subjects (16 years
old; interquartile range 10–17 years) were included in the
present study. All subjects were Caucasian. Clinical and
demographic characteristic are shown in Table 1. All verti-
cally HIV-infected subjects except one were under HAART
at the time of study. HIV-infected and healthy subjects were
similar in age and gender. A total of 25 (43.9%) vertically
HIV-infected subjects had a detectable HIV viral load. Median
CD4 T-cell counts (absolute and percentage) were signifi-
cantly lower in vertically HIV-infected subjects who pre-
sented with a detectable viral load. No further differences in
clinical and demographic characteristics were observed
between vertically HIV-infected subjects with detectable and
undetectable viral loads.
Frequencies of different CD4 T-cell subsets: premature ver-
sus chronological immunosenescence
Naive and memory CD4+ T cells were significantly increased
in vertically HIV-infected subjects when compared with
healthy subjects (Table 2 and Fig. 1a,b). Interestingly, similar
frequencies of effector memory and TemRA CD4 T cells
were observed in both groups (Table 2).
Taking advantage of the fact that in subjects who had been
vertically infected the age matched the time of HIV infection,
we analysed associations with age between vertically HIV-
infected and healthy subjects. In this regard, significant nega-
tive correlations between naive CD4 T-cell frequency and
age were observed in both healthy and vertically HIV-
infected subjects (Fig. 2a,b). The opposite was found in mem-
ory and effector memory T-cell subsets. No correlation was
observed between memory T-cell frequency and age in
healthy subjects (Fig. 2c), although in vertically HIV-infected
subjects a positive correlation was found (Fig. 2d). Moreover,
a positive correlation was observed between effector mem-
ory T-cell frequency and age in healthy subjects (Fig. 2e),
although only a trend was observed in vertically HIV-infected
subjects (Fig. 2f). Moreover, no correlations were observed
between TemRA CD4 T cells and age in healthy and in verti-
cally HIV-infected subjects (p 0.704 and p 0.630, respec-
tively).
Alterations in replicative senescence, activation and prolif-
eration markers in CD4 T-cell subsets
All phenotypic characteristics of the different CD4 T-cell
subsets are shown in Table 2. No significant alterations were
observed in the naive CD4 T-cell subset, because it
expressed similar senescence, activation and proliferation
markers in vertically HIV-infected and healthy subjects. How-
ever, although the memory T-cell subset did not show more
activation, significantly higher levels of senescence and prolif-
eration were observed in vertically HIV-infected patients
than in the healthy subjects (Fig. 3a–c). Furthermore, the
effector memory CD4 T cells of vertically HIV-infected sub-
jects displayed higher senescence, activation and proliferation
levels than healthy subjects (Fig. 3d–f). Regarding the TemRA
CD4 T-cell subset, vertically HIV-infected subjects showed
higher senescence and activation levels than healthy subjects,
but similar levels of proliferation were observed (Fig. 3g–i).
No correlations were found between immunosenescence
parameters and age in either healthy subjects or vertically
HIV-infected subjects (data not shown).
Impact of viral load levels in CD4 T-cell immune exhaustion
The cohort was divided into individuals showing detectable
and undetectable viral load to better analyse the effect of
high HIV replication (Table 2). When the CD4 T-cell subset
was analysed as a whole, only differences in the activation
levels were found, whereas both groups presented similar
TABLE 1. Clinical and demographic characteristics of the subjects
Parameter All HIV-infectedA HealthyB Detectable HIV-infectedC Undetectable HIV-infectedD p A ) B p C ) D
N 57 32 25 32
Age (years) 14 [11–17] 16 [10–17] 14 [12–16] 14 [10–18] ns ns
Gender (female (%)) 32 (56.1) 13 (70) 14 (56) 18 (56.3) ns ns
CD4 count (cells/mm3) 722 [503–994] na 550 [423–751] 828 [634–1348] na 0.003
CD4 (%) 30 [25.7–38.1] na 26.6 [19.3–33.2] 33.7 [28.5–40] na 0.008
Viral load (HIV-RNA copies/mL) 39 [39–1635]a na 1730 [260–13 600] <40 na na
Positive PCR for HCV (%) 6 (10.5) na 2 (8) 4 (12.5) na ns
Time on HAART (years) 9 [5–10] na 10 [7.5–10] 7.5 [3.5–10] na ns
HAART, highly active antiretroviral therapy; HIV, human immunodeficiency virus.
Continuous variables are expressed as median [interquartile range] and categorical variables are expressed as number of cases (%).ns, non-significant; na, not available.
aAll undetectable values were arbitrarily considered as 39.
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frequency of senescent cells and proliferation levels. Interest-
ingly, a trend for higher activation was observed in all CD4
T-cell subsets in those who presented detectable viral load
(Table 2). Moreover, a higher expression of proliferation
markers was observed in naive and memory CD4 T-cells,
whereas lower proliferation levels were detected in effector
memory and TemRA CD4 T cells in vertically HIV-infected
subjects with detectable viral loads (Table 2). On the other
hand, no higher expression of senescent markers was found
in any of the CD4 T-cell subsets in vertically HIV-infected
subjects with detectable viral load (Table 2).
Regarding time of infection, similar correlations between
CD4 T-cell subsets and age were found in vertically HIV-
infected subjects with detectable and undetectable viral loads
(data not shown).
Discussion
Our findings provide evidence that vertically HIV-infected
subjects have specific patterns of immunosenescence on
CD4 T-cell subsets. Interestingly, despite having a median of
14 years of infection, our study subjects showed a highly
preserved naive T-cell subset. Additionally, viral load levels
seem not to influence the existing accumulation of senescent
differentiated CD4 subsets.
TABLE 2. Frequencies and immunological homeostasis parameters of CD4 T-cell subsets
Variable
All HIV-infectedA
(n = 57)
HealthyB
(n = 32)
Detectable
HIV-infectedC
(n = 25)
Undetectable
HIV-infectedD
(n = 32) p A vs. B p C vs. D
Subpopulation (%)
Naive CD4 49.9 [40.0–58.1] 40 [32.7–55.7] 48.6 [34.6–58.2] 51.5 [45.5–58.3] 0.035 ns
Memory CD4 26.1 [22.0–30.5] 20.2 [16.9–30.2] 25.8 [22.1–37.2] 26.3 [21.8–29.3] 0.010 ns
Effector memory CD4 9.0 [6.3–12.9] 10 [7.2–14.4] 10.6 [6.6–17.3] 8.4 [6.3–12] ns ns
TemRA CD4 2.4 [0.7–3.7] 2 [0.6–2.6] 1.3 [0.6–5.6] 2.7 [0.8–3.7] ns ns
Total CD4 T cells (%)
CD28) CD57+ 2.5 [0.8–4.1] 0.5 [0.3–1.0] 2.6 [0.9–5.3] 2.4 [0.8–3.6] <0.001 ns
HLA) DR+ 4.7 [2.5–13.9] 4.6 [2.1–6.4] 10.9 [3.0–16.1] 3.5 [1.7–10.6] 0.163 0.016
KI67+ 2.7 [2.0–4.4] 1.9 [1.3–2.4] 3.2 [2.2–4.7] 2.5 [2.0–3.7] 0.002 ns
Naive CD4 T cells (%)
CD28) CD57+ 0.0 [0.0–0.1] 0.1 [0.0–0.1] 0.0 [0.0–0.1] 0.0 [0.0–0.1] ns ns
HLADR+ 0.3 [0.1–3.6] 0.9 [0.1–2.4] 2.7 [0.1–5.2] 0.1 [0.1–2.7] ns 0.059
KI67+ 0.2 [0.0–0.3] 0.2 [0.0–0.5] 0.3 [0.1–0.3] 0.1 [0.0–0.2] ns 0.018
Memory CD4 T cells (%)
CD28) CD57+ 0.9 [0.3–2.3] 0.2 [0.1–0.3] 1.1 [0.4–2.5] 0.6 [0.3–2.1] <0.001 ns
HLA) DR+ 2.6 [1.0–8.0] 4.5 [2.5–6.8] 6.5 [1.1–10.8] 1.6 [1.0–7.1] ns 0.068
KI67+ 3.3 [2.1–5.2] 1.4 [1.0–1.9] 3.8 [2.6–5.5] 2.9 [1.9–4.5] <0.001 0.118
Effector memory CD4 T cells(%)
CD28) CD57+ 5.7 [2.4–14.9] 1.3 [0.8–2.4] 7.6 [2.0–15.8] 5.0 [2.4–13.9] <0.001 ns
HLA) DR+ 14.1 [8.7–20.3] 5.9 [4.8–10.3] 18.9 [9.0–25.9] 12.4 [8.3–17.4] <0.001 0.051
KI67+ 10.0 [4.2–15.9] 5.4 [1.3–7.4] 8.9 [3.9–14.2] 13.5 [7.1–18.4] 0.001 0.162
TemRA CD4 T cells (%)
CD28) CD57+ 12.3 [6.4–23.7] 4.7 [2.6–6.1] 9.8 [6.1–19.7] 13.9 [6.5–24.3] <0.001 ns
HLA) DR+ 34.3 [24.4–44.3] 21.2 [10.3–30.7] 35.8 [30.7–52.5] 32.9 [20.3–41.3] 0.001 0.156
KI67+ 3.4 [2.3–7.3] 3.0 [0.6–7.4] 2.3 [1.3–4.7] 4.3 [2.4–8.9] ns 0.020
Subpopulations of CD4 T cells were quantified as a percentage of the total CD4 T cells (see subpopulation definition in the Materials and Methods section). Co-expression
of markers for replicative senescence, cellular activation and proliferation were assessed in total CD4 T-cell, and corresponding subpopulations, as percentage of cells
expressing these homeostatic markers. Variables are expressed as median [interquartile range]. HIV, human immunodeficiency virus; ns, non-significant; Tem, T effector mem-
ory.
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FIG. 1. Naive and memory CD4 subsets. Percentages of naive cells (CD45RA+ CD27+) represented within the CD4 lineage (a) and percentages
of memory T cells (CD45RO+ CD27+) represented within the CD4 lineage (b). Vertically human immunodeficiency virus (HIV) -infected subjects
(squares) and healthy subjects (circles) are represented.
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In our study, half of the HIV-infected subjects had detect-
able viral loads despite being under treatment. The high
levels of viral load in our cohort has several explanations:
poor adherence to antiretroviral therapies because of com-
ing from dysfunctional families and persistent viral failures
due to suboptimal treatments because of the limitation of
available drugs.
This is the first study that shows an exhaustive analysis
of CD4 T-cell subsets in vertically HIV-infected subjects.
Studies about immune reconstitution during HAART have
described a better capacity of vertically HIV-infected sub-
jects for naive CD4 T-cell reconstitution compared with
adults, which has been linked to a higher contribution of
the thymus [10,12,13,21–23]. When lymphocyte subsets
have been compared with healthy age-matched subjects a
lower [16] or similar [17] naive CD4 T-cell frequency has
been reported. In contrast, we have observed a higher fre-
quency of naive CD4 T cells in vertically HIV-infected sub-
jects compared with healthy subjects. Nevertheless, the
first study included untreated and mildly symptomatic HIV-
infected subjects and the second one included HIV-infected
subjects co-infected with malaria, whereas we focused on
asymptomatic HAART-treated vertically HIV-infected sub-
jects. Accordingly, exposition to the HIV in the birth canal
would possibly favour the preservation of the naive CD4
T-cell subset [14,15]. Moreover, we did not observe further
homeostatic alterations such as activation, proliferation or
acquisition of senescence-related markers affecting the naive
T-cell subset, suggesting that naive T cells could increase as
the result of the active renewal attributable to thymic out-
put with no major role of homeostatic proliferation [24].
Importantly, viral load seems not to affect the frequency of
the naive subset. Nevertheless, we cannot rule out that the
presence of viral replication is exerting a higher pressure in
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FIG. 2. Premature versus chronological immunosenescence associations. Correlations between age/period of infection and different CD4 T-cell
subsets: naive T cells in healthy subjects (a) and vertically human immunodeficiency virus (HIV) -infected subjects (b); memory T cells in healthy
subjects (c) and vertically HIV-infected subjects (d); and effector memory T cells in healthy subjects (e) and vertically HIV-infected subjects (f).
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the immune system of HIV-infected subjects with detectable
viral load, leading to a higher naive CD4 T-cell activation
and proliferation when compared with those with undetect-
able viral load.
It is generally accepted that HIV infection alters the distri-
bution of T-cell phenotypes, which may be partially normal-
ized by HAART [25,26]. In our study, despite recording a
significant increase of memory CD4 T-cell frequency, no
accumulation of effector differentiated subsets was observed
in vertically HIV-infected subjects. Therefore, our results are
consistent with the hypothesis of a persistent thymic output
of naive CD4 T cells and their conversion to the memory
subset, which would increment both subsets. Furthermore,
the concomitant absence of a marked homeostatic prolifera-
tion could explain the absence of effector accumulation.
Interestingly, the effector memory subset is expected to
accumulate in an altered T-cell homeostasis scenario [27],
which also supports our hypothesis of a preserved immune
system in vertically HIV-infected subjects. We cannot
exclude the possibility of selective depletion caused by HIV-1
infection or a higher apoptosis rate in such a subset but,
unfortunately, a limitation of this study is the lack of apopto-
sis measurements.
Additionally, we have observed a higher expression of
senescence-related and proliferation-related markers in the
expanded memory CD4 T-cell subset of vertically HIV-
infected subjects. The absence of a higher activation in this
T-cell subset may reflect the effect of HAART in reducing
CD4 T-cell activation [28]. Interestingly, viral load did not
aggravate the senescence of the memory subset, although it
was influencing its activation levels. Regarding the effector
subsets, although none accumulated in the vertically HIV-
infected subjects, both effector memory and TemRA CD4 T
cells were homeostatically altered in this scenario. It is note-
worthy that viral load also influenced the activation/prolifera-
tion levels in both effector subsets.
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To date, it is not completely understood how vertical
HIV infection influences CD4 T-cell dynamics. Under
healthy circumstances, naive CD4 T-cell frequency is high
in newborns and declines with age, whereas memory CD4
T-cell populations seem to expand with age [29]. Our
results show that in vertically HIV-infected subjects there
is negative correlation between naive CD4 T-cell frequency
and age, as occurs in healthy subjects, and memory CD4
T-cell levels positively correlated with age in vertically
HIV-infected subjects, which is also associated with the
time of infection [30]. Unexpectedly, we did not observe
such a relationship in our healthy population, probably
because of the small number of subjects, and their low
frequencies of memory cells. Moreover, the positive corre-
lation between effector memory CD4 T cells and age
observed in healthy subjects is only a trend in vertically
HIV-infected subjects, suggesting a skewed maturation pat-
tern of this subset.
Taken together, our findings suggest that HIV infection
during the maturation of the immune system could provide
some benefits possibly attributable to preserved homeostatic
mechanisms or to the high thymic function existing at the
time of HIV presentation. On the other hand, although viral
load seems not to affect the main homeostatic mechanisms
of CD4 T-cell subsets, its influence on activation levels
points to the necessity of maintaining these subjects under
suppressive therapies. Nevertheless, once vertically HIV-
infected subjects start suffering aging-associated chronological
immunosenescence, they could be at a disadvantage to con-
front new immune challenges. The clinical consequences of
this process are uncertain.
Acknowledgements
The authors would like to thank the patients participating in
this study, as well as the Paediatric Infectious Diseases Units
Virgen del Rocı´o University Hospital, Hospital General Uni-
versitario Gregorio Maran˜o´n and La Paz University Hospital
for their clinical support of the patients and the HIV BioBank
integrated in the Spanish AIDS Research Network (RIS). We
would also thank to Juan Manuel Praena Ferna´ndez for statis-
tical assistance.
Funding
This work was supported by the Spanish AIDS Research
Network of Excellence (RIS; Red de Investigacio´n en SIDA)
(RD06/0006/0021 to MMPB, RD09/0076/00103 and RD06/
0006-0035); the Consejerı´a de Salud of Junta de Andalucı´a
(PI-0366/07); the Consejerı´a de Innovacio´n, Ciencia y Empre-
sa (P10-CTS-6313); the Fundacio´n para la Investigacio´n y la
prevencio´n del SIDA en Espan˜a (FIPSE) (366884/07 to GML
and 240800/09, 300509); the Fondos de Investigacio´n Sani-
taria (FIS) (Miguel Servet Grants CP07/00240 to YMP, CP07/
00117 to RC and CP08/0172 to ERM and Sara Borrell
Grants CD10/00382 to SFM); Comunidad de Madrid (S-SAL-
0159-2006) and Paediatric European Network for treatment
of AIDS (PENTA to MAMF).
Transparency Declaration
The authors declare that there were no conflicts of interest.
References
1. Fortuny C, Noguera-Julian A, Alsina L et al. Impact of CD4 T cell
count on the outcome of planned treatment interruptions in early-
treated human immunodeficiency virus-infected subjects. Pediatr Infect
Dis J 2011; 30: 435–438.
2. European Collaborative Study. Mother-to-child transmission of HIV
infection in the era of highly active antiretroviral therapy. Clin Infect
Dis 2005; 40: 458–465.
3. Violari A, Cotton MF, Gibb DM et al. Early antiretroviral therapy and
mortality among HIV-infected infants. N Engl J Med 2008; 359: 2233–
2244.
4. Desai S, Landy A. Early immunosenescence in HIV disease. Curr HIV/
AIDS Rep 2010; 7: 4–10.
5. Deeks SG. HIV infection, inflammation, immunosenescence, and
aging. Annu Rev Med 2011; 62: 141–155 (Review).
6. Molina-Pinelo S, Vallejo A, Dı´az L et al. Premature immunosenes-
cence in HIV-infected patients on highly active antiretroviral therapy
with low-level CD4 T cell repopulation. J Antimicrob Chemother 2009;
64: 579–588.
7. Appay V, Sauce D. Immune activation and inflammation in HIV-1
infection: causes and consequences. J Pathol 2008; 214: 231–241.
8. Kelley CF, Kitchen CM, Hunt PW et al. Incomplete peripheral CD4+
cell count restoration in HIV-infected patients receiving long-term an-
tiretroviral treatment. Clin Infect Dis 2009; 48: 787–794.
9. Douek DC, McFarland RD, Keiser PH et al. Changes in thymic func-
tion with age and during the treatment of HIV infection. Nature 1998;
396: 690–695.
10. Franco JM, Leon-Leal JA, Leal M et al. CD4+ and CD8+ T lymphocyte
regeneration after anti-retroviral therapy in HIV-1-infected subjects
and adult patients. Clin Exp Immunol 2000; 119: 493–498.
11. Ometto L, De Forni D, Patiri F et al. Immune reconstitution in HIV-
1-infected subjects on antiretroviral therapy: role of thymic output
and viral fitness. AIDS 2002; 16: 839–849.
12. Correa R, Mun˜oz-Ferna´ndez MA. Effects of highly active antiretroviral
therapy on thymical reconstitution of CD4 T lymphocytes in verti-
cally HIV-infected subjects. AIDS 2002; 16: 1181–1183.
13. Correa R, Mun˜oz-Ferna´ndez MA. Production of new T cells by thy-
mus in subjects: effect of HIV infection and antiretroviral therapy. Pe-
diatr Res 2002; 52: 207–212.
14. Hainaut M, Ducarme M, Schandene L et al. Age-related immune
reconstitution during highly active antiretroviral therapy in human
564 Clinical Microbiology and Infection, Volume 19 Number 6, June 2013 CMI
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 19, 558–565
immunodeficiency virus type 1-infected subjects. Pediatr Infect Dis J
2003; 22: 62–69.
15. Weinberg A, Dickover R, Britto P et al. Continuous improvement in
the immune system of HIV-infected subjects on prolonged antiretro-
viral therapy. AIDS 2008; 22: 2267–2277.
16. Ananworanich J, Apornpong T, Kosalaraksa P et al. PREDICT Study
Group. Characteristics of lymphocyte subsets in HIV-infected, long-
term nonprogressor and healthy Asian subjects through 12 years of
age. J Allergy Clin Immunol 2010; 126: 1294–301.e10.
17. Sewanyana I, Baker CA, Ruel T et al. The distribution and immune
profile of T cell subsets in HIV-infected subjects from Uganda. AIDS
Res Hum Retroviruses 2009; 25: 65–71.
18. Garcı´a-Merino I, de Las Cuevas N, Jime´nez JL et al. Pediatric HIV Bio-
Bank: a new role of the Spanish HIV BioBank in pediatric HIV
research. AIDS Res Hum Retroviruses 2010; 26: 241–244.
19. Ferrando-Martinez S, Ruiz-Mateos E, Leal M. CD27 and CCR7
expression on naive T cells, are both necessary? Immunol Lett 2010;
127: 157–158.
20. de Martino M, Rossi ME, Azzari C et al. Different meaning of CD38
molecule expression on CD4+ and CD8+ cells of subjects perinatally
infected with human immunodeficiency virus type 1 infection surviv-
ing longer than five years. Pediatr Res 1998; 43: 752–758.
21. Sleasman JW, Nelson RP, Goodenow MM et al. Immunoreconstitu-
tion after ritonavir therapy in subjects with human immunodeficiency
virus infection involves multiple lymphocytes lineages. J Pediatr 1999;
134: 597–606.
22. Gibb DM, Newberry A, Klein N et al., Paediatric European Network
for Treatment of AIDS (PENTA) Steering Committee Immune repop-
ulation after HAART in previously untreated HIV-1-infected subjects.
Lancet 2000; 355: 1331–1332.
23. Vigano A, Vella S, Saresella M et al. Early immune reconstitution after
potent antiretroviral therapy in HIV-infected subjects correlates with
the increase in thymus volume. AIDS 2000; 14: 251–261.
24. Blais ME, Brochu S, Giroux M et al. Why T cells of thymic versus ex-
trathymic origin are functionally different. J Immunol 2008; 180: 2299–
2312.
25. Rosenblatt HM, Stanley KE, Song LY et al. Immunological response to
highly active antiretroviral therapy in subjects with clinically stable
HIV-1 infection. J Infect Dis 2005; 192: 445–455.
26. Anselmi A, Vendrame D, Rampon O et al. Immune reconstitution in
human immunodeficiency virus type 1-infected subjects with different
virological responses to anti-retroviral therapy. Clin Exp Immunol
2007; 150: 442–450.
27. Cao W, Jamieson BD, Hultin LE et al. Premature aging of T cells is
associated with faster HIV-1 disease progression. J Acquir Immune De-
fic Syndr 2009; 50: 137–147.
28. Resino S, Navarro J, Bello´n JM et al. Naı¨ve and memory CD4+ T cells
and T cell activation markers in HIV-1 infected subjects on HAART.
Clin Exp Immunol 2001; 125: 266–273.
29. Hazenberg MD, Otto SA, van Rossum AM et al. Establishment of the
CD4+ T-cell pool in healthy subjects and untreated subjects infected
with HIV-1. Blood 2004; 104: 3513–3519.
30. Srinivasula S, Lempicki RA, Adelsberger JW et al. Differential
effects of HIV viral load and CD4 counts on proliferation of naive
and memory CD4 and CD8 T lymphocytes. Blood 2011; 118: 262–
70.
CMI Me´ndez Lagares et al. CD4 immunosenescence in vertical infection 565
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 19, 558–565
